Emcure Pharmaceuticals
Tracked across 3 events · 21 articles · First seen Nov 10, 2025 · Last active Sep 17, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Emcure gains full control of Gennova, streamlining operations and focusing on biologics and biosimilars. The deal is financially neutral but strategically positive.
Jul 13, 2026 · 7 articles
Regulatory
Impact: Emcure received CDSCO approval to market Poviztra for MASH, expanding its product portfolio and potential revenue stream.
Jul 20, 2026 · 8 articles
Business
Abbott Laboratories announced on September 17, 2026 a royalty-free, non-exclusive voluntary licensing agreement with Gilead Sciences covering investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreement is intended to support manufacturing readiness,…
Impact: One of five other partners that signed voluntary licensing agreements with Gilead Sciences for twice-yearly lenacapavir.
Sep 17, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Emcure Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard